{"id":770,"date":"2024-11-23T18:11:07","date_gmt":"2024-11-23T18:11:07","guid":{"rendered":"http:\/\/sips-es.org\/?p=770"},"modified":"2024-11-23T18:11:07","modified_gmt":"2024-11-23T18:11:07","slug":"based-on-these-observations-a-possible-scenario-for-a-therapeutic-use-of-immunotherapy-targeting-pathological-tau-would-be-as-follows","status":"publish","type":"post","link":"https:\/\/sips-es.org\/?p=770","title":{"rendered":"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows"},"content":{"rendered":"

\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows. phenotype. These antibodies enter the brain and bind to pathological tau within neurons. We are currently clarifying further the mechanism of action of this promising therapeutic approach and determining its epitope specificity. Keywords: Amyloid-, tau, immunotherapy, vaccine, immunization INTRODUCTION An emerging therapeutic approach for protein conformational disorders is usually immune modulation to clear the characteristic assemblies and aggregates of the pathological proteins [114]. This promising approach was originally based primarily on studies showing that immunization with aggregated A1?42 reduces A plaque burden and associated pathology in mouse brains [110]. Prior and subsequent studies indicated that this effect was likely to be antibody-mediated [11, 14, 23, 25, 67, 116, 120, 122], and resulted in cognitive improvements [30, 56, 62, 86]. Following and during these promising mouse studies, clinical trials were initiated using aggregated A1?42 along with QS-21 adjuvant that promotes cytotoxic T-cell response [57]. These trials were subsequently halted because of meningoencephalitis observed in a small Pax1<\/a> subset of patients [96, 109]. The clinical symptoms, when they occurred, and subsequent histopathological analysis in two patients indicated that this encephalitis was likely T-cell mediated directly related to the vaccination, caused by the antigen and\/or adjuvant and probably not related to the A antibodies [36, 90, 96]. However, positive preliminary findings have emerged from this trial, and refinement of this approach is currently Eltrombopag Olamine underway. Four autopsies from the trial have shown plaque clearance but Eltrombopag Olamine vascular amyloid and most of the tau pathology remained [36, 79, 89, 90]. Tau aggregates within plaque-associated dystrophic neurites appeared to have been cleared as those neurites disappeared with the removal of the plaques. However, tangles and neurophil threads remained, emphasizing the need for therapy that directly targets pathological tau. Two of the four autopsy subjects did not develop encephalitis, indicating that reduced amyloid burden is not a consequence of brain inflammation. Regarding cognitive improvements, in the Zurich cohort there was a positive correlation between the presence of antibodies that acknowledged A in tissue sections [51] and a less pronounced cognitive decline [52]. More recently, a report from the Phase I study of AN-1792 showed less decline in a cognitive test compared to untreated age-matched controls [15]. In the larger Phase IIa trial, cognitive improvement was not obvious although z-score analyses across the neuropsychological test battery indicated that this antibody responders differed from the placebo subjects [42]. Overall, these preliminary findings on cognitive effects and A clearance raise hopes for the future of A-based immunotherapy. A derivatives\/antibodies and other adjuvants are being explored with the aim of reducing potential side effects while maintaining or improving therapeutic efficacy. However, it should be stressed that the current findings from the A vaccine trials indicate as well that it is unlikely that targeting A alone will be sufficient in most subjects that are already experiencing cognitive decline. IMPROVING THE SAFETY OF A IMMUNOTHERAPY Prior to the side effects in the AN-1792 trial, we raised concerns about administering full-length A1?42 in humans, and we advocated the use of adjuvants that favor a Th2 response promoting antibody production instead of a Th1 response which mediates a cytotoxic T-cell response [120]. The primary objective in designing our A derivatives was to maintain antibody epitopes while reducing their -sheet content compared to A to eliminate direct toxicity and amyloid seeding potential. These modifications also altered or removed potential T-cell epitopes; hence, modulation of the immune response was to be expected. Interestingly, recent findings in the prion field indicate also that immune responses to -helical structures appear to involve more the Th2 pathway whereas -sheet conformation favors Th1 activation [58]. Our initial report was on K6A1?30 which contains 6 lysines to increase immunogenicity and reduce -sheet propensity. This peptide elicited a similar antibody response as A1?42 in mice which resulted in a comparable therapeutic efficacy [120]. Our findings with other A derivatives with diminished T-cell reactivity and modest anti-A antibody titers indicate that a strong immune response towards A is not needed to improve cognition, and for certain immunogens, IgM response correlated with reduction in A burden [9, Eltrombopag Olamine<\/a> 111, 116]. As IgM is usually unlikely to enter the brain.<\/p>\n","protected":false},"excerpt":{"rendered":"

\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows. phenotype. These antibodies enter the…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32],"tags":[],"class_list":["post-770","post","type-post","status-publish","format-standard","hentry","category-mannosidase"],"yoast_head":"\n\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows - Expression of TNF inhibitor in Senescence and Aging<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sips-es.org\/?p=770\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows - Expression of TNF inhibitor in Senescence and Aging\" \/>\n<meta property=\"og:description\" content=\"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows. phenotype. These antibodies enter the…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sips-es.org\/?p=770\" \/>\n<meta property=\"og:site_name\" content=\"Expression of TNF inhibitor in Senescence and Aging\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-23T18:11:07+00:00\" \/>\n<meta name=\"author\" content=\"webmaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"webmaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sips-es.org\\\/?p=770#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sips-es.org\\\/?p=770\"},\"author\":{\"name\":\"webmaster\",\"@id\":\"https:\\\/\\\/sips-es.org\\\/#\\\/schema\\\/person\\\/ba9c02660de1ee9c6abe6b592a373d09\"},\"headline\":\"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows\",\"datePublished\":\"2024-11-23T18:11:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sips-es.org\\\/?p=770\"},\"wordCount\":696,\"articleSection\":[\"Mannosidase\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sips-es.org\\\/?p=770\",\"url\":\"https:\\\/\\\/sips-es.org\\\/?p=770\",\"name\":\"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows - Expression of TNF inhibitor in Senescence and Aging\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sips-es.org\\\/#website\"},\"datePublished\":\"2024-11-23T18:11:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/sips-es.org\\\/#\\\/schema\\\/person\\\/ba9c02660de1ee9c6abe6b592a373d09\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sips-es.org\\\/?p=770#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sips-es.org\\\/?p=770\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sips-es.org\\\/?p=770#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/sips-es.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sips-es.org\\\/#website\",\"url\":\"https:\\\/\\\/sips-es.org\\\/\",\"name\":\"Expression of TNF inhibitor in Senescence and Aging\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sips-es.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sips-es.org\\\/#\\\/schema\\\/person\\\/ba9c02660de1ee9c6abe6b592a373d09\",\"name\":\"webmaster\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b43a6959056f061bfce2b9742be3cc647b70a6a44c84e7d0bcc557ddb9e81d78?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b43a6959056f061bfce2b9742be3cc647b70a6a44c84e7d0bcc557ddb9e81d78?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b43a6959056f061bfce2b9742be3cc647b70a6a44c84e7d0bcc557ddb9e81d78?s=96&d=mm&r=g\",\"caption\":\"webmaster\"},\"sameAs\":[\"http:\\\/\\\/sips-es.org\"],\"url\":\"https:\\\/\\\/sips-es.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows - Expression of TNF inhibitor in Senescence and Aging","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sips-es.org\/?p=770","og_locale":"en_US","og_type":"article","og_title":"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows - Expression of TNF inhibitor in Senescence and Aging","og_description":"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows. phenotype. These antibodies enter the…","og_url":"https:\/\/sips-es.org\/?p=770","og_site_name":"Expression of TNF inhibitor in Senescence and Aging","article_published_time":"2024-11-23T18:11:07+00:00","author":"webmaster","twitter_card":"summary_large_image","twitter_misc":{"Written by":"webmaster","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sips-es.org\/?p=770#article","isPartOf":{"@id":"https:\/\/sips-es.org\/?p=770"},"author":{"name":"webmaster","@id":"https:\/\/sips-es.org\/#\/schema\/person\/ba9c02660de1ee9c6abe6b592a373d09"},"headline":"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows","datePublished":"2024-11-23T18:11:07+00:00","mainEntityOfPage":{"@id":"https:\/\/sips-es.org\/?p=770"},"wordCount":696,"articleSection":["Mannosidase"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/sips-es.org\/?p=770","url":"https:\/\/sips-es.org\/?p=770","name":"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows - Expression of TNF inhibitor in Senescence and Aging","isPartOf":{"@id":"https:\/\/sips-es.org\/#website"},"datePublished":"2024-11-23T18:11:07+00:00","author":{"@id":"https:\/\/sips-es.org\/#\/schema\/person\/ba9c02660de1ee9c6abe6b592a373d09"},"breadcrumb":{"@id":"https:\/\/sips-es.org\/?p=770#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sips-es.org\/?p=770"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/sips-es.org\/?p=770#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sips-es.org\/"},{"@type":"ListItem","position":2,"name":"\ufeffBased on these observations, a possible scenario for a therapeutic use of immunotherapy targeting pathological tau would be as follows"}]},{"@type":"WebSite","@id":"https:\/\/sips-es.org\/#website","url":"https:\/\/sips-es.org\/","name":"Expression of TNF inhibitor in Senescence and Aging","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sips-es.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/sips-es.org\/#\/schema\/person\/ba9c02660de1ee9c6abe6b592a373d09","name":"webmaster","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b43a6959056f061bfce2b9742be3cc647b70a6a44c84e7d0bcc557ddb9e81d78?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b43a6959056f061bfce2b9742be3cc647b70a6a44c84e7d0bcc557ddb9e81d78?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b43a6959056f061bfce2b9742be3cc647b70a6a44c84e7d0bcc557ddb9e81d78?s=96&d=mm&r=g","caption":"webmaster"},"sameAs":["http:\/\/sips-es.org"],"url":"https:\/\/sips-es.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/sips-es.org\/index.php?rest_route=\/wp\/v2\/posts\/770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sips-es.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sips-es.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sips-es.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sips-es.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=770"}],"version-history":[{"count":1,"href":"https:\/\/sips-es.org\/index.php?rest_route=\/wp\/v2\/posts\/770\/revisions"}],"predecessor-version":[{"id":771,"href":"https:\/\/sips-es.org\/index.php?rest_route=\/wp\/v2\/posts\/770\/revisions\/771"}],"wp:attachment":[{"href":"https:\/\/sips-es.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sips-es.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sips-es.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}